Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates 

March 17, 2026 4:06 PM EDT

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough

On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026

Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028

Management to host a conference call and webcast today at 4:30 p.m. ET

NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) --... More